Opus Genetics, Inc.

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other ophthalmic disorders. Its lead product candidate is OPGx-LCA5, a gene therapy for LCA5-associated IRD currently in Phase 1/2 clinical trials. The company also has a pipeline of preclinical programs, including OPGx-BEST1 for BEST1-associated retinal disease, OPGx-RHO for autosomal dominant retinitis pigmentosa caused by RHO mutations, OPGx-RDH12 for retinal dystrophy due to RDH12 mutations, OPGx-MERTK for MERTK IRD, OPGx-NMNAT1 for NMNAT1-related retinal degeneration, and OPGx-CNGB1 for retinitis pigmentosa from CNGB1 mutations. Additionally, Opus Genetics develops Phentolamine Ophthalmic Solution for mydriasis reversal, presbyopia, and night vision disturbances, as well as APX3330, a small-molecule Ref-1 inhibitor for diabetic retinopathy.

Opus Genetics, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol IRD. The company is based in the United States and trades in U.S. dollars (USD). As a Nasdaq-listed company, it is subject to the reporting and governance requirements of the U.S. Securities and Exchange Commission (SEC). Investors can buy and sell shares of IRD through brokerage accounts that offer access to U.S. stock exchanges.

Opus Genetics, Inc. operates in the Healthcare sector and is classified under the Biotechnology industry. As a biotechnology company, it focuses on developing innovative therapies using biological processes, specifically gene therapy, to address medical conditions. In this case, the company targets inherited retinal diseases and other ophthalmic disorders, leveraging its expertise in gene augmentation and small-molecule inhibitors. The biotechnology industry is characterized by high research and development costs, long development timelines, and significant regulatory oversight, but also offers the potential for breakthrough treatments that can transform patient care.

Opus Genetics, Inc. is headquartered in the United States, as indicated by its country of incorporation being the United States and its region being 'us'. The company primarily serves the U.S. market, but as a biopharmaceutical company developing treatments for inherited retinal diseases, its therapies have the potential to address global unmet medical needs. The company's clinical trials and regulatory filings are likely conducted with the U.S. Food and Drug Administration (FDA), and its products, if approved, would initially be marketed in the United States. The company's focus on rare genetic eye diseases means its patient population is global, but its current operations and market focus are centered in the U.S.

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company, meaning it does not yet have approved products generating revenue. Its business model involves developing gene therapies and other treatments for ophthalmic diseases through research and development, with the goal of obtaining regulatory approval and commercializing these therapies. The company's pipeline includes several preclinical and clinical-stage programs, such as OPGx-LCA5 (Phase 1/2), Phentolamine Ophthalmic Solution, and APX3330. If approved, revenue would come from sales of these therapies. Additionally, the company may generate revenue through partnerships, licensing agreements, or collaborations with other pharmaceutical companies. As of now, Opus Genetics is pre-revenue and focuses on advancing its pipeline to create future value for shareholders.